ruxolitinib (as phosphate), 5mg, 15mg, - Ruxolitinib - Document - PDFSEARCH.IO

First Page		Document Content
Janus kinase inhibitor Placebo Thrombocytosis Polycythemia vera Splenomegaly Leukemia Medicine Ruxolitinib Myelofibrosis		ruxolitinib (as phosphate), 5mg, 15mg, & 20mg tablets (Jakavi®) SMC No[removed]Novartis Pharmaceuticals UK Ltd. 06 February 2015 The Scottish Medicines Consortium (SMC) has completed its assessment of the above produc Add to Reading List Source URL: www.scottishmedicines.org.uk Download Document from Source Website File Size: 211,95 KB Share Document on Facebook

	HAEMATOLOGY AUDIT TEMPLATE DocID: 1pL02 - View Document
	Needham & Company 15th Annual Healthcare Conference John Scarlett, M.D. President & CEO, Geron Corporation April 12, 2016 DocID: 1pn6V - View Document
	1 Dr Jürgen Thiele Institute for Pathology University of Cologne Kerpener Str. 62 DocID: 1ohLr - View Document
	Phase 2 trial of PRM-151, an anti-fibrotic agent, in patients with myelofibrosis: Stage 1 results Srdan Verstovsek1, Ruben Mesa2, Lynda Foltz3, Vikas Gupta4, John Mascarenhas5, Ellen Ritchie6, Ronald Hoffman5, Richard DocID: 19YPO - View Document
	Novartis Pharmaceuticals Canada Inc. 385 Bouchard Blvd. Dorval, Quebec Canada H9S 1A9 www.novartis.ca DocID: 19fx5 - View Document